Abstracts Archive - Page 837 of 2607 - ACR Meeting Abstracts

Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Akhil Sood¹, Arbi Galestanian¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
Abstract Number: 0009 • ACR Convergence 2020
Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases
Zakaria El Ouali¹, Elie Bassa¹, Abdoul-Rahamane Halidou Idrissa¹, Sarah Tazi¹, Samy Housbane², Mohamed Bennani Othmani², Kawtar Nassar¹ and Saadia Janani¹, ¹Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, ²Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco
Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…
Abstract Number: 0010 • ACR Convergence 2020
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
Michael Putman¹, Yu Pei Eugenia Chock², Herman Tam³, Alfred Kim⁴, Sebastian Sattui⁵, Francis Berenbaum⁶, Maria (Maio) Danila⁷, Peter Korsten⁸, Catalina Sanchez Alvarez⁹, Jeffrey Sparks¹⁰, Laura Coates¹¹, Candace Palmerlee¹², Andrea Pierce¹³, Arundathi Jayatilleke¹⁴, Sindhu Johnson¹⁵, Adam Kilian¹⁶, Jean Liew¹⁷, Larry Prokop⁹, Hassan Murad⁹, Rebecca Grainger¹⁸, Zachary Wallace¹⁹ and Ali Duarte-Garcia⁹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Greenwich, CT, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Washington University School of Medicine, St. Louis, MO, ⁵Hospital for Special Surgery, New York, NY, ⁶Sorbonne Universit�, Paris, France, ⁷University of Alabama at Birmingham (UAB), Birmingham, AL, ⁸University Medical Center Göttingen, Gottingen, Germany, ⁹Mayo Clinic, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Oxford, Oxford, United Kingdom, ¹²12. Patient Research Partner, Berkeley, CA, ¹³Patient Research Partner, New York City, ¹⁴Lewis Katz School of Medicine, Temple University, Philadelphia, PA, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶George Washington University, Washington, DC, ¹⁷University of Washington, Seattle, WA, ¹⁸University of Otago, Wellington, New Zealand, ¹⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. There has been particular interest in the antimalarial agent…
Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
David Simon¹, Koray Tascilar¹, Gerhard Krönke², Arnd Kleyer¹, Mario Zaiss³, Franz Heppt⁴, Christine Meder⁴, Raja Atreya⁵, Entcho Klenske⁵, Peter Dietrich⁵, Abdullah Abdullah⁵, Thorsten Kliem⁵, Giulia Corte⁶, Harriet Morf³, Moritz Leppkes⁵, Andreas Kremer⁵, Andreas Ramming³, Milena Pachowsky⁷, Florian Schuch⁸, Monika Ronneberger⁹, Stefan Kleinert¹⁰, Clara Maier¹¹, Axel Hueber¹², Karin Manger¹³, Bernhard Manger³, Carola Berking⁴, Matthias Tenbusch¹¹, Klaus Überla¹¹, Michael Sticherling³, Markus Neurath⁵ and Georg Schett¹⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, ⁷Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, ⁹Rheumatology Clinical Practice Erlangen, Erlangen, Germany, ¹⁰Rheumatology-Nephrology Practice, Erlangen, Germany, ¹¹Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ¹³Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Kristin Wipfler¹, Yomei Shaw², Teresa Simon³, Adam Cornish¹, Bryant England⁴, Alexis Ogdie⁵, Patricia Katz⁶ and Kaleb Michaud⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, East Lansing, MI, ³Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of California, San Francisco, Novato, CA
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…
Abstract Number: 0013 • ACR Convergence 2020
Colchicine to Weather the Storm in Hospitalized Patients with COVID-19
Luigi Brunetti¹, Oumou Diawara¹, Andrew Tsai², Bonnie Firestein³, Ronald Nahass⁴, George Poiani⁵ and Naomi Schlesinger⁶, ¹Rutgers Ernest Mario School of Pharmacy, piscataway, NJ, ²Center of Excellence in Pharmaceutical Translational Research and Education, piscataway, NJ, ³Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, piscataway, NJ, ⁴Robert Wood Johnson University Hospital Somerset, somerset, NJ, ⁵Rutgers Robert Wood Johnson Medical School, somerset, NJ, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection, is a global pandemic causing havoc. There is a knowledge gap regarding…
Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Fernando López-Gutierrez¹, Antía García-Fernández¹, Jesús Loarce-Martos¹, Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Veronica Garcia², Boris Blanco-Cáceres¹, Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
Abstract Number: 0015 • ACR Convergence 2020
COVID -19 Lung Inflammation – What Have We Learnt so Far ?
Sriya Gokaraju¹, Maria Darda², Vinod Vijayaraghavan Nalini Warrier³, Irina Duta³, Fiona Hayes³, Yasser Ahmed⁴ and Gouri Koduri³, ¹Southend University Hospital NHS Trust, Essex, United Kingdom, ²Southend University Hospital NHS Trust, Essex, United Kingdom, ³Southend University Hospital NHS Trust, Essex, United Kingdom, ⁴Southend University Hospital, Essex, United Kingdom
Background/Purpose: The SARS CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of pneumonia and Acute Respiratory Distress Syndrome (ARDS). SARS CoV-2 in…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0017 • ACR Convergence 2020
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
Daniel Watrous¹, Glenn Parris², Priya Reddy³, Jeffrey Alper⁴, Fenglong Xie⁵, Maria (Maio) Danila⁶, Michael George⁷, William Nowell⁸, Joel Kallich⁹ and Jeffrey R Curtis¹⁰, ¹Sierra Pacific Arthritis, Visalia, CA, ²PARRIS & ASSOCIATES, Lilburn, GA, ³Southwest Florida Rheumatology, Riverview, FL, ⁴Medallion Clinical Research Institute, LLC, Naples, FL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Global Healthy Living Foundation, New York City, NY, ⁹Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The global COVID19 pandemic has had a major impact on healthcare. The effect on rheumatology patients and providers is unclear, as is the role…
Abstract Number: 0018 • ACR Convergence 2020
PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
Gregory Vitone¹, Marianna Frey², Candace Feldman³, Lindsay Lally², Anne Bass⁴, Jane Salmon², Mary Crow², Michael Lockshin⁵, Vivian Bykerk², Medha Barbhaiya⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Little is known about the general health and wellbeing of patients with systemic rheumatic diseases (SRD) during the COVID pandemic. We sought to compare…
Abstract Number: 0019 • ACR Convergence 2020
Lasting COVID-19 Impacts on US Rheumatology Practices
Lynn Price¹, Gianna Melendez¹ and Phil Pouliot¹, ¹spherix global insights, Exton, PA
Background/Purpose: In late 2019, a novel, highly contagious coronavirus (COVID-19), was discovered in China and quickly spread throughout the world, equating to arguably the largest…
Abstract Number: 0020 • ACR Convergence 2020
Characteristics of Rheumatology Outpatients with Suspected or Confirmed COVID-19 During the Pandemic in New York City
Medha Barbhaiya¹, Gregory Vitone², Marianna Frey³, Deanna Jannat-Khah⁴, Candace Feldman⁵, Lindsay Lally³, Anne Bass⁶, Jane Salmon³, Mary Crow³, Michael Lockshin¹, Vivian Bykerk³ and Lisa Mandl³, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York City, NY, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: The incidence and disease severity of COVID-19 in rheumatic disease patients, who may be at higher risk due to underlying immune dysregulation and use…
Abstract Number: 0021 • ACR Convergence 2020
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Dominique Kinnett-Hopkins¹, Linda Ehrlich-Jones², Holly Milaeger³, Alanna Kenney³, Lorena Rosiles³ and Rosalind Ramsey-Goldman⁴, ¹Northwestern University, Chicago, IL, ²Shirley Ryan AbilityLab, Chicago, ³Northwestern University, Chicago, ⁴Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…
Abstract Number: 0022 • ACR Convergence 2020
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Andrew Heisler¹, Jing Song², Lutfiyya Muhammad³, Alyssa Wohlfahrt⁴, Wendy Marder⁵, Marcy Bolster⁶, Clifton Bingham III⁷, Daniel Clauw⁸, Dorothy Dunlop⁹, Tuhina Neogi¹⁰ and Yvonne Lee³, ¹Northwestern University Feinberg School of Medicine, Oak Park, IL, ²Northwestern University, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Brigham and Womans Hospital, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Massachusetts General Hospital, Concord, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸Michigan Medicine, Ann Arbor, MI, ⁹Northwestern University, New Haven, CT, ¹⁰Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have abnormalities in central nervous system regulation of pain, leading to enhanced pain sensitivity at joint sites (peripheral sensitization)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].